Findings from recently published placebo-controlled trials in idiopathic pulmonary fibrosis
have established that pirfenidone and nintedanib prevent about 50% of the decline in forced …

In The Lancet today, Paul Noble and colleagues report the results of the CAPACITY
programme (Clinical Studies Assessing Pirfenidone in idiopathic pulmonary fibrosis …

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …

Background In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are
low. Thus prospective mortality trials are logistically very challenging, justifying the use of …

Despite the development of pharmacological therapies that are effective in slowing the
progression of idiopathic pulmonary fibrosis (IPF), it remains a debilitating and lethal …

Currently many questions remain regarding the use of pirfenidone and nintedanib in IPF,
including which drug to prescribe, the optimal patient population to treat, the duration of …

Over the past two and a half decades, many clinical trials have been designed to determine
the safety and efficacy of pharmacotherapy for patients with idiopathic pulmonary fibrosis …

Idiopathic pulmonary fibrosis (IPF) currently affects about 100 000 individuals in the US, and
millions globally. Patients living with IPF experience disabling symptoms and progressive …

Idiopathic Pulmonary Fibrosis (IPF) now has two licensed treatments available. Pirfenidone
was the first drug to be licensed and approved for use, followed by nintedanib. We set out …

Background The treatment landscape for idiopathic pulmonary fibrosis, a devastating lung
disease, is changing. To investigate the effectiveness of treatments for idiopathic pulmonary …